Press Releases

Press Releases

Date Title  
Mar 08, 2021
Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021
Superior profile of novel anti-tau antibody PRX005 supports advancement for the potential treatment of Alzheimer’s disease New analyses of prasinezumab continue to support potential disease modifying effect of prasinezumab in Parkinson’s disease; Roche expected to initiate Phase 2b PADOVA study in
Feb 24, 2021
Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
Robust preclinical data support the benefit of PRX005, a novel anti-tau antibody, for the potential treatment Alzheimer’s disease New pre-specified exploratory subgroup analyses and new digital biomarker data from Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early
Feb 11, 2021
Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
Net cash used in operating and investing activities was $19.1 million in the fourth quarter and $80.6 million for the full year 2020; quarter-end cash and restricted cash position of $298.1 million provides funding to advance the R&D pipeline Announced confirmatory Phase 3 AFFIRM-AL study of
Feb 05, 2021
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that in
Feb 04, 2021
Prothena to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast Conference Call on February 11th
DUBLIN, Ireland , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, announced today that it will
Feb 01, 2021
Prothena Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA
Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months) SPA agreement with FDA to enable registration of birtamimab at unprecedented p
Dec 09, 2020
Prothena Reports Positive 9 Month Results from Phase 1 Long-term Extension Study of PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis
Slowing of neuropathy   progression for all 7 evaluable patients ,   evidenced by   a +1.29 point mean change in NIS ,   was   more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of – 3.33 points
Dec 04, 2020
Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that
Nov 04, 2020
Prothena Reports Third Quarter 2020 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $19.5 million   in the third quarter and $61.4 million for the first nine months of 2020; quarter-end cash and restricted cash position of $317.2 million provides funding to advance the R&D pipeline Roche presented results from the Phase 2
Nov 04, 2020
Prothena Announces Presentations on Two Programs from its Alzheimer’s Disease Portfolio at CTAD 2020
Next generation anti- Aβ   antibod ies being developed for subcutaneous administration to improve access for patient s   with Alzheimer’s disease Multi- i mmunogen Aβ- t au va ccine being developed for the prevention and treatment of Alzheimer’s disease DUBLIN, Ireland , Nov.